Full Breakdown
Landmark Progress in Xenotransplantation: Genetically Modified Pig Kidneys in Humans
9/8/2025, 8:32:50 PM
Successful Transplants Mark a New Era
In a significant advancement for xenotransplantation, Tim Andrews, a 67-year-old man from Concord, New Hampshire, has remained dialysis-free for over seven months following a transplant of a genetically modified pig kidney. This achievement represents the longest survival of a pig organ in a human to date. Andrews received the kidney on January 25, 2025, as part of a compassionate use program facilitated by the biotechnology company eGenesis, based in Cambridge, Massachusetts. He had previously endured end-stage kidney disease and over two years of dialysis treatment.
Bill Stewart, a 54-year-old athletic trainer from Dover, New Hampshire, is the second recipient of an eGenesis pig kidney, having undergone the transplant on June 14, 2025. Stewart was discharged from Massachusetts General Hospital a week later and has also been able to discontinue dialysis. Both patients are part of a broader effort to explore the viability of pig organs as a solution to the critical organ shortage in the United States, where over 100,000 individuals are currently on the transplant waiting list, predominantly for kidneys.
Background on Xenotransplantation
Xenotransplantation involves transplanting organs from one species to another, and the use of genetically modified pigs aims to address the biological incompatibilities that have historically hindered such procedures. The kidneys used in these transplants have undergone multiple genetic modifications, including the elimination of three antigens to reduce the risk of rejection and the addition of seven human genes to mitigate inflammation and bleeding complications.
Official Statements & Responses
Dr. Leonardo Riella, the medical director for kidney transplantation at Massachusetts General Hospital, described the FDA's recent approval of clinical trials for eGenesis' genetically engineered kidneys as a "big milestone." He emphasized the potential of these trials to provide new options for patients suffering from end-stage kidney disease. Mike Curtis, president and CEO of eGenesis, noted that the trials will allow researchers to better understand how these organs perform across a diverse patient population.
Criticism & Opposition
Despite the optimism surrounding these advancements, there are concerns regarding the long-term viability of pig organs in humans. Previous attempts at xenotransplantation have faced challenges, including organ rejection and complications arising from the patients' underlying health conditions. Critics argue that while these initial successes are promising, more extensive trials are necessary to ensure the safety and efficacy of such transplants.
What's Next
The FDA has approved eGenesis to initiate a clinical trial involving 30 patients aged 50 and older who are on dialysis and the transplant waiting list. This trial aims to evaluate the safety and effectiveness of the EGEN-2784 pig kidneys in a broader patient population. United Therapeutics, another company involved in developing gene-edited pig organs, is also preparing to start its own human trials.
Verbatim Quotes
- “It's going to be the option for people that don't want to be on dialysis, they want to be able to be with their kids and loved ones.” — Tim Andrews
- “I really wanted to contribute to the science of it,” — Bill Stewart
- “Clearance of the EGEN-2784 IND and initiation of this clinical study are important steps forward in our mission to end the global organ shortage,” — Mike Curtis, eGenesis President and CEO
- “A year, hopefully longer than that – that’s already a huge advantage,” — Dr. Leonardo Riella
As researchers continue to explore the potential of xenotransplantation, the experiences of Andrews and Stewart may pave the way for new treatment options for countless patients facing kidney failure.
